Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

AXL is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer.

Axelrod HD, Valkenburg KC, Amend SR, Hicks JL, Parsana P, Torga G, De Marzo AM, Pienta KJ.

Mol Cancer Res. 2018 Oct 5. pii: molcanres.0718.2018. doi: 10.1158/1541-7786.MCR-18-0718. [Epub ahead of print]

PMID:
30291220
2.

Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis.

Ma S, Ogino S, Parsana P, Nishihara R, Qian Z, Shen J, Mima K, Masugi Y, Cao Y, Nowak JA, Shima K, Hoshida Y, Giovannucci EL, Gala MK, Chan AT, Fuchs CS, Parmigiani G, Huttenhower C, Waldron L.

Genome Biol. 2018 Sep 25;19(1):142. doi: 10.1186/s13059-018-1511-4.

3.

Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging.

Nimmagadda S, Pullambhatla M, Chen Y, Parsana P, Lisok A, Chatterjee S, Mease R, Rowe SP, Lupold S, Pienta KJ, Pomper MG.

J Nucl Med. 2018 Mar;59(3):486-493. doi: 10.2967/jnumed.117.191221. Epub 2017 Oct 12.

4.

Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration.

Parsana P, Amend SR, Hernandez J, Pienta KJ, Battle A.

BMC Cancer. 2017 Jun 26;17(1):447. doi: 10.1186/s12885-017-3413-3.

5.

Correction: The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer.

Shiozawa Y, Berry JE, Eber MR, Jung Y, Yumoto K, Cackowski FC, Yoon HJ, Parsana P, Mehra R, Wang J, McGee S, Lee E, Nagrath S, Pienta KJ, Taichman RS.

Oncotarget. 2017 Jun 6;8(23):38075. doi: 10.18632/oncotarget.18369. No abstract available.

6.

Impact of the X Chromosome and sex on regulatory variation.

Kukurba KR, Parsana P, Balliu B, Smith KS, Zappala Z, Knowles DA, Favé MJ, Davis JR, Li X, Zhu X, Potash JB, Weissman MM, Shi J, Kundaje A, Levinson DF, Awadalla P, Mostafavi S, Battle A, Montgomery SB.

Genome Res. 2016 Jun;26(6):768-77. doi: 10.1101/gr.197897.115. Epub 2016 Apr 21.

7.

The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer.

Shiozawa Y, Berry JE, Eber MR, Jung Y, Yumoto K, Cackowski FC, Yoon HJ, Parsana P, Mehra R, Wang J, McGee S, Lee E, Nagrath S, Pienta KJ, Taichman RS.

Oncotarget. 2016 Jul 5;7(27):41217-41232. doi: 10.18632/oncotarget.9251. Erratum in: Oncotarget. 2017 Jun 6;8(23 ):38075.

8.

OVOL guides the epithelial-hybrid-mesenchymal transition.

Jia D, Jolly MK, Boareto M, Parsana P, Mooney SM, Pienta KJ, Levine H, Ben-Jacob E.

Oncotarget. 2015 Jun 20;6(17):15436-48.

9.

Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure.

Verdone JE, Parsana P, Veltri RW, Pienta KJ.

Prostate. 2015 Feb;75(2):218-24. doi: 10.1002/pros.22908. Epub 2014 Oct 18.

10.

The presence of androgen receptor elements regulates ZEB1 expression in the absence of androgen receptor.

Mooney SM, Parsana P, Hernandez JR, Liu X, Verdone JE, Torga G, Harberg CA, Pienta KJ.

J Cell Biochem. 2015 Jan;116(1):115-23. doi: 10.1002/jcb.24948.

11.

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.

Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB.

Oncotarget. 2013 Nov;4(11):2067-79.

Supplemental Content

Loading ...
Support Center